IRADIMED CORP — Form 8-K
Filed October 30, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Iradimed reported Q3 2026 revenue of $24.2 million, a 14% increase from $21.2 million in Q3 2025 and 18% sequentially. GAAP diluted EPS was $0.51 (vs. $0.43 in Q3 2025); non-GAAP diluted EPS was $0.55 (vs. $0.47). The company declared a $0.20 per share quarterly cash dividend payable November 27, 2026. Full-year 2026 guidance was revised to $91.6–$93.1M revenue (narrowed from $91.0–$96.0M), with GAAP diluted EPS of $1.90–$1.94 (narrowed from $1.90–$2.05).
Why this rating
Solid Q3 growth and record bookings, but guidance revision narrowed upside; dividend return signals confidence. Material for $480M company but ordinary quarterly execution.
See more from October 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.